BBIO Q4 2024 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+237.1% YoY

Gross Profit

$4M64.6% margin

Operating Income

-$226M-3842.7% margin

Net Income

-$265M-4506.1% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

+115.3%

Cash Flow

Operating Cash Flow

-$195M

Free Cash Flow

-$199M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$919M

Total Liabilities

$2.4B

Stockholders' Equity

-$1.5B

Cash & Equivalents

$681M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+237.1%
Gross Profit	$4M	$1M	+231.1%
Operating Income	-$226M	-$177M	-27.4%
Net Income	-$265M	-$168M	-57.6%